Request a Proposal  

Pharm-Olam Blog

News

Pharm-olam is a global clinical research organization that delivers right-sized trial services to pharmaceutical, biotechnology, government, and public health organizations around the world.

Blog Feature

Press Release | COVID-19

By: Renee Butler
May 20th, 2021

HOUSTON, Texas, May 10, 2021 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare and orphan diseases along with oncology, is now enrolling volunteers in the United Kingdom into a pivotal Phase III COVID-19 vaccine study. Visit ukcovid19study.com for more information about participation. The Phase III “Cov-Compare” trial (VLA2001-301) will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria [1], in a comparative immunogenicity trial. There will be roughly 4,000 people participating in this study. Pharm-Olam is the full-service provider for this study, utilizing leading technology platforms.

Blog Feature

Press Release | COVID-19

By: Jason Ezzelle
January 19th, 2021

HOUSTON, Texas, January 4, 2021 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a treatment against the inflammatory response and associated complications brought on by COVID-19.

GDPR_Checklist-cover

Join other Clinical Development experts to get the latest industry news, trends and insights.

As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist

Blog Feature

Press Release

By: John W Colby III
October 8th, 2020

HOUSTON, Texas, October 8, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures (MCMs).

Blog Feature

Press Release | COVID-19

By: John W Colby III
September 23rd, 2020

HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO will provide project management, contract management, and clinical trial site support to participating military treatment facility investigative sites. Pharm-Olam will be partnering with The Geneva Foundation (Geneva), which is dedicated to serving military medical researchers with the on-site support needed to operationalize clinical trials.

Blog Feature

By: John W Colby III
June 24th, 2020

Houston, June 24, 2020 – Pharm-Olam, a global midsized clinical research organization (CRO), today announced that they completed a change of ownership transaction on Friday June 19, 2020. This transaction provides Pharm-Olam with enhanced financial flexibility and access to additional capital to support its growth strategy, as it continues to enhance their services in the company’s five core therapeutic areas: oncology-hematology, infectious disease and vaccines, autoimmune, allergy and rare disease.

Blog Feature

Pharm-Olam Insights | Press Release

By: John W Colby III
June 16th, 2020

Houston, June 16th, 2020 – Pharm-Olam, LLC, a global, midsized CRO offering full-service clinical development solutions to the pharmaceutical and biotech industry, is launching Protocol Optimization Services to support the study development needs of their biopharma clients. The Protocol Optimization Service will benchmark a sponsor’s study design against other similar clinical trials and identify optimization opportunities for consideration and inclusion. This service will aid the development of lean and cost-effective study design while also maximizing study value through balancing patient and site burden with the achievement of planned primary and secondary study endpoints.

Blog Feature

Press Release

By: John W Colby III
April 29th, 2020

HOUSTON, TX, April 29, 2020– Pharm-Olam, a leading mid-sized clinical research organization (CRO) serving the pharmaceutical and biotech industry, won multiple recognitions in Life Science Leader magazine’s 2020 CRO Leadership Awards. This year marks the second consecutive year in which Pharm-Olam won CRO Leadership Awards. In 2019, the clinical research organization received awards in Compatibility, Reliability, and Quality. Building on that operational success, Pharm-Olam received awards in five of the six categories recognized by Life Science Leader. Pharm-Olam won a 2020 CRO Leadership Award in the following categories:

Blog Feature

Press Release

By: John W Colby III
April 27th, 2020

Collaboration between Pharm-Olam and IAOCR ensures “quality built in” audits Houston, Texas and Maidenhead, United Kingdom, 27 April 2020 – The first Independently Accredited Clinical Research Audit Academy is registering delegates for its first cohort commencing 4 May. “Audit Academy” blends high-quality virtual training and development facilitated by Pharm-Olam, with robust, independent and internationally-recognized accreditation awarded by IAOCR to deliver Internationally Qualified Clinical Research Auditors (designatory letters AIACR1).